AIM ImmunoTech Inc. (AIM): Forward P/S Multiple
AIM ImmunoTech generates stable income based on the uniqueness of the Ampligen drug. The expected price-to-sales ratio on the GURU.Markets daily chart confirms this trend, where the indicator level stands at 60.40. The therapy's independence from economic cycles guarantees business resilience, while the modernization of laboratories is currently preparing the company to increase the production volumes of new clinical series.
Analytical breakdowns for AIM ImmunoTech
- current price and projected stock value:
- stock exchange capitalization data:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital AIM ImmunoTech|AIM - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity AIM ImmunoTech Inc.|AIM - Company Total Debt|Debt to Book Capitalization Ratio AIM ImmunoTech Inc.|AIM - Company Long-Term Liabilities|Company Current Liabilities AIM ImmunoTech|Quick Liquidity aimimmuno.com
- business earnings and investment ratios data:
AIM - Company Profit|Expected Profit AIM ImmunoTech|AIM - Market Cap to Earnings|Projected Price to Earnings AIM ImmunoTech|AIM - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple AIM ImmunoTech Inc.|AIM - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) AIM ImmunoTech|AIM - Net earnings per share for the last 12 months|Quarterly EPS earnings growth aimimmuno.com|AIM - Earnings per share increase in current year|Earnings growth forecast for next year AIM ImmunoTech
- sales and revenue data:
Analysis of all company metrics:AIM (AIM ImmunoTech)
To assess the fundamental value of AIM ImmunoTech (AIM), investors must compare current market capitalization with projected sales volumes. Analyzing the forward P/S ratio allows for the tracking of market expectations prior to earnings releases, where an increase in this metric reflects confidence in the therapeutic potential of Ampligen, despite the ambiguous perception of the company among a broad circle of retail traders.
Competitors of AIM ImmunoTech (AIM)
Forward P/S Multiple ARGX (argenx)|Forward P/S Multiple BioNTech Inc. BNTX|Abivax Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio ADMA Corp ADMA|Protagonist Therapeutics (PTGX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple immunovant.com|Forward Price-to-Revenue Multiple KNSA|GRFS: Forward Price to Sales|Forward P/S Multiple ADPT|Market Cap to Expected Sales Ratio Celldex Corp|Price-to-Projected Revenue Ratio Aurinia Pharmaceuticals AUPH|BCRX - Forward Price-to-Revenue Multiple|VERA - Price-to-Projected Revenue Ratio|Dianthus Therapeutics Inc (DNTH) - Forward Price-to-Revenue Multiple|PHVS (Pharvaris Corp) - Forward Price-to-Revenue Multiple|AbCellera Corp (ABCL) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Tourmaline Bio, Inc.|Market Cap to Projected Revenue PGEN (precigen.com)|Price-to-Projected Revenue Ratio Pharming Group (PHAR)|NKTR - Market Cap to Future Revenue Ratio|Upstream Bio Corp - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio ZBIO (Zenas Corp)|Immunome, Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio gossamerbio.com|KALV: Forward P/S Multiple|Forward Price-to-Revenue Multiple Septerna, Inc.|PVLA (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|SVRA: Forward Price to Sales|Forward P/S Multiple RIGL|Forward P/S Multiple anaptysbio.com (ANAB)|Forward P/S Multiple ATXS (Astria Therapeutics, Inc.)|Market Cap to Expected Sales Ratio enGene Holdings Inc (ENGN)|RAPT - Price-to-Projected Revenue Ratio|Aerovate Therapeutics Inc (JBIO) - Forward Price-to-Revenue Multiple|Aclaris Therapeutics (ACRS) - Price-to-Projected Revenue Ratio|Future Price to Revenue KYTX (kyvernatx.com)|TLSA (Tiziana Life Sciences Ltd) - Forward P/S Multiple|CABA: Forward Price to Sales|Forward P/S Multiple VTYX|Forward P/S Multiple Theratechnologies, Inc (THTX)|Price-to-Projected Revenue Ratio Avalo Therapeutics, Inc AVTX|Forward Price to Sales ELDN|AGEN - Price-to-Projected Revenue Ratio|Climb Bio Inc. (CLYM) - Forward Price-to-Revenue Multiple|ZURA: Forward P/S Multiple|aTyr Pharmaceuticals (ATYR) - Forward P/S Multiple|Forward Price-to-Revenue Multiple ADAG|IMA: Forward Price to Sales|Forward P/S Multiple STTK|Market Cap to Expected Sales Ratio equilliumbio.com|Price-to-Projected Revenue Ratio Connect Biopharma Holdings Limited CNTB|IMUX - Forward Price-to-Revenue Multiple|ATRA - Price-to-Projected Revenue Ratio|InflaRx N.V. (IFRX) - Forward Price-to-Revenue Multiple|XFOR (X4 Pharmaceuticals, Inc.) - Forward Price-to-Revenue Multiple|Adicet Bio, Inc. (ACET) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Celularity Inc|Market Cap to Projected Revenue INMB (INmune Bio Corporation)|Forward P/S Multiple BRNS|KZR - Market Cap to Future Revenue Ratio|Forward P/S Multiple SABS (SAB Biotherapeutics, Inc.)|Forward P/S Multiple Akari Therapeutics PLC AKTX|Enlivex Therapeutics, Ltd. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Q32 Bio Inc. QTTB|GeoVax Labs, Inc. (GOVX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple edesabiotech.com|Forward Price-to-Revenue Multiple IBIO|CARM: Forward Price to Sales|Forward P/S Multiple XTLB|Market Cap to Expected Sales Ratio boltbio.com|Price-to-Projected Revenue Ratio HCW Biologics HCWB|APVO - Forward Price-to-Revenue Multiple|ADTX - Price-to-Projected Revenue Ratio|GRI Bio Inc (GRI) - Forward Price-to-Revenue Multiple|XRTX (XORTX) - Forward Price-to-Revenue Multiple|Vyome Therapeutics (HIND) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Revelation Biosciences|Market Cap to Projected Revenue INDP (indaptusrx.com)|Price-to-Projected Revenue Ratio Scinai Immunotherapeutics Ltd. (SCNI)|CALI - Market Cap to Future Revenue Ratio|Affimed N.V. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio ALLK (Allakos Inc)|HOOKIPA - Forward P/S Multiple|Market Cap to Future Revenue Ratio IGM Biosciences, Inc.|ITOS: Forward P/S Multiple|Forward Price-to-Revenue Multiple Ocean Biomedical Inc|TCBP (TC BioPharm (Holdings) PLC) - Forward P/S Multiple|THRD: Forward Price to Sales
